Condition: Glioblastoma · Anaplastic Astrocytoma · Sponsor: The Methodist Hospital Research Institute
Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in newly diagnosed glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA).
This description comes directly from the study's public registry record.
David S. Baskin, MD · 713-441-3803 or 713-201-5792 · DBaskin@houstonmethodist.org
Helga M. Jones · 713-363-9388 · HMJones@houstonmethodist.org
Always discuss trial participation with your own doctor first.
| Houston Methodist Neurological Institute | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03603405